怎么服用万赛维？

Valcyte is an oral anti-cytomegalovirus infection drug developed by the Swiss company Roche. Its main ingredient is valganciclovir hydrochloride. It is currently used to treat induction therapy of CMV retinitis, maintenance therapy of CMV retinitis and prevention of CMV infection in transplant patients.

How should patients take Valcyte?

Usage and dosage of Valcyte tablets: Note: The basic requirement to avoid drug overdose is to strictly follow the recommended dosage. Standard dosage: Vancevi tablets are administered orally and should be taken with food. Vansevir tablets can be rapidly converted into ganciclovir in large quantities. The bioavailability of Valcyte tablets (Valcyte) as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, so the Valcyte tablets (Valcyte) dosage and usage instructions described below should be strictly followed. Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation. Special Dosage Guidelines in Patients with Renal Impairment: Serum creatinine or creatinine clearance levels should be monitored closely. Dosage adjustments should be made based on creatinine clearance as shown below. For CrCl≥(greaterthanorequalto)60mL/min, the induction dose is 900mg, twice a day; the maintenance dose is 900mg, once a day. For CrCl 40-59mL/min, the induction dose is 450mg, twice a day; the maintenance dose is 450mg, once a day. If the CrCl is 25-39mL/min, the induction dose is 900mg, once a day; the maintenance dose is 900mg, once every other day. For CrCl 10-24mL/min, the induction dose is 900mg, once every other day; the maintenance dose is 900mg, twice a week. The creatinine clearance rate can be estimated based on serum creatinine according to the following formula: Male = [140-age (years) x weight (kg) ÷ (72) x [0.011x serum creatinine (umol/L)]. Female=0.85×male value. Patients undergoing hemodialysis: For patients undergoing hemodialysis (CrCl<10mL/min), no recommended dosage can be given, so valganciclovir hydrochloride tablets cannot be used for such patients. Cases of severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, myelosuppression and aplastic anemia have occurred in patients treated with: (or cyclovir). Do not start treatment with Valganciclovir Hydrochloride Tablets if the absolute neutrophil count is less than 500/uL, the platelet count is less than 25,000/uL, or the hemoglobin is less than 8 g/dl.